Cargando…

Discovery of anti-inflammatory physiological peptides that promote tissue repair by reinforcing epithelial barrier formation

Epithelial barriers that prevent dehydration and pathogen invasion are established by tight junctions (TJs), and their disruption leads to various inflammatory diseases and tissue destruction. However, a therapeutic strategy to overcome TJ disruption in diseases has not been established because of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Oda, Yukako, Takahashi, Chisato, Harada, Shota, Nakamura, Shun, Sun, Daxiao, Kiso, Kazumi, Urata, Yuko, Miyachi, Hitoshi, Fujiyoshi, Yoshinori, Honigmann, Alf, Uchida, Seiichi, Ishihama, Yasushi, Toyoshima, Fumiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597994/
https://www.ncbi.nlm.nih.gov/pubmed/34788088
http://dx.doi.org/10.1126/sciadv.abj6895
Descripción
Sumario:Epithelial barriers that prevent dehydration and pathogen invasion are established by tight junctions (TJs), and their disruption leads to various inflammatory diseases and tissue destruction. However, a therapeutic strategy to overcome TJ disruption in diseases has not been established because of the lack of clinically applicable TJ-inducing molecules. Here, we found TJ-inducing peptides (JIPs) in mice and humans that corresponded to 35 to 42 residue peptides of the C terminus of alpha 1-antitrypsin (A1AT), an acute-phase anti-inflammatory protein. JIPs were inserted into the plasma membrane of epithelial cells, which promoted TJ formation by directly activating the heterotrimeric G protein G13. In a mouse intestinal epithelial injury model established by dextran sodium sulfate, mouse or human JIP administration restored TJ integrity and strongly prevented colitis. Our study has revealed TJ-inducing anti-inflammatory physiological peptides that play a critical role in tissue repair and proposes a previously unidentified therapeutic strategy for TJ-disrupted diseases.